Varicella-Zoster Virus Reactivation After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation, Single-Center Experience of Acyclovir Prophylaxis

被引：1

作者：

Arici, Galip ^{[1
]}

Ince, Elif ^{[2
]}

Ince, Erdal ^{[3
]}

Ileri, Talia ^{[2
]}

Ciftci, Ergin ^{[4
]}

Dogu, Figen ^{[5
]}

Ozdemir, Halil ^{[4
]}

Cakmakli, Hasan Fatih ^{[2
]}

Ertem, Mehmet ^{[2
]}

机构：

[1] Etlik City Hosp, Dept Pediat Cardiol, Ankara, Turkiye

[2] Ankara Univ, Fac Med, Dept Pediat Hematol, Ankara, Turkiye

[3] Mem Hosp, Dept Pediat, Ankara, Turkiye

[4] Ankara Univ, Fac Med, Dept Pediat Infect, Ankara, Turkiye

[5] Ankara Univ, Fac Med, Dept Pediat Allergy & Immunol, Ankara, Turkiye

来源：

PEDIATRIC TRANSPLANTATION | 2024年 / 28卷 / 05期

关键词：

acyclovir prophylaxis; hematopoietic stem cell transplantation; herpes zoster; varicella-zoster virus; BONE-MARROW-TRANSPLANTATION; HERPES-ZOSTER; RISK-FACTORS; INFECTION; CHILDREN; DISEASE;

D O I：

10.1111/petr.14819

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

BackgroundVaricella-zoster virus (VZV) reactivation is the most common infectious complication in the late posthematopoietic stem cell transplantation (HSCT) period and is reported as 16%-41%. Acyclovir prophylaxis is recommended for at least 1 year after HSCT to prevent VZV infections. However, studies on the most appropriate prophylaxis are ongoing in pediatric patients.MethodsPatients who underwent allogeneic HSCT between January 1, 1996 and January 1, 2020 were retrospectively analyzed to outline the characteristics of VZV reactivation after allogeneic HSCT in pediatric patients using 6 months acyclovir prophylaxis.ResultsThere were 260 patients and 273 HSCTs. Median age was 10.43 (0.47-18.38), and 56% was male. Median follow-up was 2325 days (18-7579 days). VZV reactivation occurred in 21.2% (n = 58) at a median of 354 (55-3433) days post-HSCT. The peak incidence was 6-12 months post-HSCT (43.1%). Older age at HSCT, female gender, history of varicella infection, lack of varicella vaccination, low lymphocyte, CD4 count, and CD4/CD8 ratio at 9 and 12 months post-HSCT was found as a significant risk for herpes zoster (HZ) in univariate analysis, whereas history of varicella infection and low CD4/CD8 ratio at 12 months post-HSCT was an independent risk factor in multivariate analysis.ConclusionsTailoring acyclovir prophylaxis according to pre-HCT varicella history, posttransplant CD4 T lymphocyte counts and functions, and ongoing immunosuppression may help to reduce HZ-related morbidity and mortality. Varicella-zoster virus (VZV) reactivation is the most common infectious complication in the late posthematopoietic stem cell transplantation (HSCT) period and is reported as 16%-41%. Acyclovir prophylaxis is recommended for at least 1 year after HSCT to prevent VZV infections. However, there is less information on pediatric patients and studies on the most appropriate prophylaxis are ongoing.image

引用

页数：8

共 50 条

[21] Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation [J].

Kawamura, Koji ;

Wada, Hidenori ;

Yamasaki, Ryoko ;

Ishihara, Yuko ;

Sakamoto, Kana ;

Ashizawa, Masahiro ;

Sato, Miki ;

Machishima, Tomohito ;

Terasako, Kiriko ;

Kimura, Shun-ichi ;

Kikuchi, Misato ;

Nakasone, Hideki ;

Yamazaki, Rie ;

Kanda, Junya ;

Kako, Shinichi ;

Tanihara, Aki ;

Nishida, Junji ;

Kanda, Yoshinobu .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 19 :26-32

[22] Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience [J].

Yoshida, Shohei ;

Fujii, Nobuharu ;

Kamoi, Chihiro ;

Kitamura, Wataru ;

Fujiwara, Hideaki ;

Asada, Noboru ;

Nishimori, Hisakazu ;

Fujii, Keiko ;

Matsuoka, Ken-ichi ;

Maeda, Yoshinobu .

ACTA MEDICA OKAYAMA, 2022, 76 (03) :247-253

[23] Visceral varicella zoster virus infection after allogeneic stem cell transplantation [J].

Doki, N. ;

Miyawaki, S. ;

Tanaka, M. ;

Kudo, D. ;

Wake, A. ;

Oshima, K. ;

Fujita, H. ;

Uehara, T. ;

Hyo, R. ;

Mori, T. ;

Takahashi, S. ;

Okamoto, S. ;

Sakamaki, H. .

TRANSPLANT INFECTIOUS DISEASE, 2013, 15 (03) :314-318

[24] Recovery of Varicella-Zoster Virus-Specific T Cell Immunity after T Cell-Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation [J].

Distler, Eva ;

Schnuerer, Elke ;

Wagner, Eva ;

von Auer, Charis ;

Plachter, Bodo ;

Wehler, Daniela ;

Huber, Christoph ;

Kolbe, Karin ;

Meyer, Ralf Georg ;

Herr, Wolfgang .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (12) :1417-1424

[25] Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis [J].

Baumrin, Emily ;

Cheng, Matthew P. ;

Kanjilal, Sanjat ;

Ho, Vincent T. ;

Issa, Nicolas C. ;

Baden, Lindsey R. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (08) :1642-1647

[26] Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients [J].

Aoki, Takahiro ;

Koh, Katsuyoshi ;

Kawano, Yutaka ;

Mori, Makiko ;

Arakawa, Yuki ;

Kato, Motohiro ;

Hanada, Ryoji .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (04) :771-775

[27] Varicella-zoster virus infection in children with hematopoietic stem cell transplants [J].

Maltezou, HC ;

Petropoulos, D ;

Gardner, M ;

Abi-Said, D ;

Mantzouranis, EC ;

Rolston, KVI ;

Chan, KW .

INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, 1998, 5 (05) :345-351

[28] Allogeneic hematopoietic stem cell transplantation: A single-center experience, 2017 to 2021 [J].

da Silva, Patricia Cristina Lopes ;

Muzzi, Guilherme Campos ;

Vilela, Maressa Ribeiro ;

Fabreti-Oliveira, Raquel A. .

TRANSPLANT IMMUNOLOGY, 2024, 82

[29] Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation [J].

Koji Kawamura ;

Jin Hayakawa ;

Yu Akahoshi ;

Naonori Harada ;

Hirofumi Nakano ;

Kazuaki Kameda ;

Tomotaka Ugai ;

Hidenori Wada ;

Ryoko Yamasaki ;

Yuko Ishihara ;

Kana Sakamoto ;

Masahiro Ashizawa ;

Miki Sato ;

Kiriko Terasako-Saito ;

Shun-ichi Kimura ;

Misato Kikuchi ;

Hideki Nakasone ;

Rie Yamazaki ;

Junya Kanda ;

Shinichi Kako ;

Aki Tanihara ;

Junji Nishida ;

Yoshinobu Kanda .

International Journal of Hematology, 2015, 102 :230-237

[30] A Japanese single-hospital observational trial with a retrospective case-control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantation [J].

Mawatari, M. ;

Isoda, A. ;

Miyazawa, Y. ;

Sawamura, M. ;

Matsumoto, M. .

TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (04) :544-550

← 1 2 3 4 5 →